Jade Biosciences, Inc. (JBIO) Research
Jade Biosciences, Inc. operates as a biotechnology enterprise, primarily focused on pioneering superior therapeutic solutions for significant unmet medical requirements in autoimmune disorders. Its leading development candidate, JADE-001, specifically targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway, aiming to treat immunoglobulin A (IgA) nephropathy. Clinical trials for JADE-001 are slated to commence in the latter half of 2025, with initial results projected for the first half of 2026. Beyond this lead asset, the company's robust pipeline includes two preclinical antibody programs, JADE-002 and JADE-003.
Market snapshot
- Symbol
- JBIO
- Price
- $16.82
- Day change
- -0.30%
- Market cap
- $548.8M
- P/E ratio
- -7.50x
- 52-week range
- 6.67-28
- Sector
- Healthcare
- Industry
- Biotechnology
- Next earnings
- in 2 months
- Analyst price target
- $44.33
Recent news
- Why Is Jade Biosciences Stock Trading Lower On Monday?
Jade Biosciences, Inc. (NASDAQ:JBIO) reported interim Phase 1 results for JADE101 in immunoglobulin A nephropathy (IgAN), showing substantial and sustained reductions in immunoglobulin A (IgA), a favorable safety profile, and pharmacokinetic data that could support a convenient dosing schedule.
Peer companies
Recent insider activity
- CAIN CHRISTOPHER W. — A-Award (34843 shares) on 2026-06-09
- DOBMEIER ERIC — A-Award (34843 shares) on 2026-06-09
- Klein Lawrence Otto — A-Award (34843 shares) on 2026-06-09
- Lavelle Erin — A-Award (34843 shares) on 2026-06-09
- Fairmount Funds Management LLC — A-Award (34843 shares) on 2026-06-09
Open Jade Biosciences, Inc. (JBIO) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.